TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Visual Analogue Scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of patients without THV dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of patients without correct hemodynamic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of parent-child relationship
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Best corrected distance visual acuity of the operated eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management of leg ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: FFI
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduced incidence of pregnancy complications in the mother
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Increased childbirth by normal methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduced incidence of low birth weight babies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Post-operative Ileus (POI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anastomotic Leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complications of Clavien-Dindo grade higher than 2
Endpoint domain: Adverse events/effects
Primary endpoint: Bowel Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in chronic body pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intense migraines or headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Missed Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Global Absence of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: complete or partial remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of words correctly phonemically segmented
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined 28-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Self reported autonomic nervous system symptoms in the past year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self reported autonomic nervous system symptoms in the past month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurobehavioral symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concentration of IPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with CIPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recovery in patients with CIPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Fatigue (PROMIS-Fatigue)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Fatigue (FACT-F)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants free from tumor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Colenbrander-1M visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lower Extremity Function Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity levels as measured by activity monitor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intraocular Pressure Change (Baseline to 24 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure Change (Baseline to 30 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgery Success Rate (24 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Surgery Success Rate (30 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Forced expiratory volume in one second (FEV1) and Forced vital capacity (FVC) ratio: FEV1/FVC Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of blood levels of FGF23 unsuitable for hypophosphatemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Total Particular Mass (TPM) exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker of Bone Formation (PINP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biomarker of Bone Resorption (CTx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean and median HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse Device Effect (ADE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Maintenance of healthy weight in the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal knee extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in acute phase reactants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for intravenous rehydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction with the efficacy of the study medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood and sputum matrix metalloproteinase-12 (MMP12) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar destruction quantified using CT and MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Liver Fat Content (LFC) at Week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of RAG-01
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in non-invasive keratographic tear breakup time (NIKBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sarcopenia scale measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Errors of commission after 28-day consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative charges and reimbursement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of advanced lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Compliance with Dreem 3S
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Consensus sleep staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Change in right ventricular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: participant-reported measures of surgeon communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of life survey using SF-6D v2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pattern of Microbial infection based on sputum culture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pattern of antimicrobial sensitivities based on sputum culture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in Osseointegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in soft tissue healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Addiction Severity Index-Lite Version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revised Mental Health Inventory- 5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Readiness to Change Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptoms of GSM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoothness of arm movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One Year Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of consumed analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted Mean Change in Schiff Sensitivity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who experience at least one treatment-emergent AE
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who discontinue due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who meet the markedly abnormal criteria for vital sign measurements at least once post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who meet the markedly abnormal criteria for safety ECG parameters at least once post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants who meet the markedly abnormal criteria for safety laboratory tests at least once post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Quebec questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Goniometer: To measure range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spike ripple rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Combat Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of participants with high grade, treatment-emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral task performance related to affective processing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: behavioral task performance related to cognitive processing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Painful Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Corneal Epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incomplete platelet aggregation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Brief Mood Introspection Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum Beta Endorphin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of episodes of relapse to acute malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lumbar JOA Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Parkinson's Disease Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 10 meter walking speed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall Efficiency Scale - International
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: recurrence of hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Haemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Macular perfusion - FAZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular perfusion - SVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular perfusion - DVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Inflammation Levels at 30±5 Days Post-Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Inflammation Levels at 90±5 Days Post-Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baseline-adjusted iGFR at 8 weeks after randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Baseline-adjusted iGFR at the end of the drug wash-out period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Baseline-adjusted levels of serum biomarkers of increased ESKD risk at the end of the drug wash-out period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relative Change in Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Device- and Procedure-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Grade 3-4 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of cardiac edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite endpoint of all-cause death or hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: hernia rate
Endpoint domain: Adverse events/effects
Primary endpoint: Procedure completion success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Days Alive and Free of Organ Support to Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day All Cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Days Free of Assisted Ventilation to Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent of Patients in Remission at One Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear amount of midpalatal suture opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive performance of the score for bacteremia or fungemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in Z-score of the trained EEG parameter(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in absolute power value of the trained EEG parameter(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in scores of the Social Responsiveness Scale 2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate and Severity of Treatment-emergent AEs (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Intradialytic Hypotensive (IDH) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Total Hemoglobin (Hgb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Free Hemoglobin (Hgb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MAP-time integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Real-time oral anticancer medication adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MD Anderson Symptom Inventory for acute myeloid leukemia/myelodysplastic syndrome (MDASI)-(AML)/MDS survey response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of complete closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in vaginal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in vulvovaginitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of adverse events and severe adverse events within 28 days after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of injection site reaction within 28 days after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of abnormal lab findings which have clinical significance within 28 days after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate evaluated at 28 days by investigator at maximum frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of adverse events and severe adverse events within 12 weeks after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Detectability of piracetam in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve Extrapolated From Time 0 to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve Extrapolated From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction with the organization, presentation and personalization of the BHSP content
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in plantar load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of cigarettes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarette craving scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent correct on an inhibitory control GoGo/NoGo task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: number of surgical procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Level of adherence to the ERAS guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: EBOV GP IgG rate at S24 post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evaluation rates per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and frequency of abnormal clinical laboratory parameter values
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change from Baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from Baseline in safety labs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from Baseline in overall interpretation of the ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of eye preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe Postpartum Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum level of adenosine deaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum level of IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regressive genetic trajectory of KRAS gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Insulin Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in horizontal bone dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Alleviation of paresthesias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Meet the Markedly Abnormal Criteria for 12-lead Electrocardiogram (ECG) or Telemetry Parameters at Least Once Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Meet the Markedly Abnormal Criteria for Laboratory Values at Least Once Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque Index, PLI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Xerostomia questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Treatment Sites with Complete Wound Closure Without Additional Autografting at Month 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Durable Wound Closure of the Study Treatment Sites Without Additional Autografting at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of newly diagnosed AF or atrial flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes